Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in other clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
The safety of MONJUVI in patients with relapsed or refractory DLBCL was evaluated in L-MIND [see Clinical Studies (
14.1)]. Patients (N = 81) received MONJUVI 12 mg/kg intravenously in combination with lenalidomide for a maximum of 12 cycles, followed by MONJUVI as monotherapy until disease progression or unacceptable toxicity as follows:
- Cycle 1: Days 1, 4, 8, 15, and 22 of the 28-day cycle;
- Cycles 2 and 3: Days 1, 8, 15, and 22 of each 28-day cycle;
- Cycles 4 and beyond: Days 1 and 15 of each 28-day cycle.
Among patients who received MONJUVI, 57% were exposed for 6 months or longer, 42% were exposed for greater than one year, and 24% were exposed for greater than two years.
Serious adverse reactions occurred in 52% of patients who received MONJUVI. Serious adverse reactions in ≥ 6% of patients included infections (26%), including pneumonia (7%) and febrile neutropenia (6%). Fatal adverse reactions occurred in 5% of patients who received MONJUVI, including cerebrovascular accident (1.2%), respiratory failure (1.2%), progressive multifocal leukoencephalopathy (1.2%), and sudden death (1.2%).
Permanent discontinuation of MONJUVI or lenalidomide due to an adverse reaction occurred in 25% of patients and permanent discontinuation of MONJUVI due to an adverse reaction occurred in 15%. The most frequent adverse reactions which resulted in permanent discontinuation of MONJUVI were infections (5%), nervous system disorders (2.5%), and respiratory, thoracic and mediastinal disorders (2.5%).
Dosage interruptions of MONJUVI or lenalidomide due to an adverse reaction occurred in 69% of patients and dosage interruptions of MONJUVI due to an adverse reaction occurred in 65%. The most frequent adverse reactions which required a dosage interruption of MONJUVI were blood and lymphatic system disorders (41%) and infections (27%).
The most common adverse reactions (≥ 20%) were neutropenia, respiratory tract infection, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, and decreased appetite.
Table 4 summarizes the adverse reactions in L-MIND.
Table 4: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Who Received MONJUVI in L-MIND| Adverse Reaction | MONJUVI in Combination with Lenalidomide
(N = 81)
|
|---|
All Grades
(%) | Grade 3 or 4
(%) |
|---|
Blood and lymphatic system disorders
|
| Neutropenia | 51 | 49 |
| Anemia | 36 | 7 |
| Thrombocytopenia | 31 | 17 |
| Febrile neutropenia | 12 | 12 |
| Infections |
| Respiratory tract infection | 51 | 12 |
| Urinary tract infection | 17 | 4.9 |
General disorders and administration site conditions
|
| Fatigue | 38 | 3.7 |
| Pyrexia | 24 | 1.2 |
| Peripheral edema | 24 | 0 |
Gastrointestinal disorders
|
| Diarrhea | 36 | 1.2 |
| Constipation | 17 | 0 |
| Abdominal pain | 15 | 1.2 |
| Nausea | 15 | 0 |
| Vomiting | 15 | 0 |
Respiratory, thoracic and mediastinal disorders
|
| Cough | 26 | 1.2 |
| Dyspnea | 12 | 1.2 |
Metabolism and nutrition disorders
|
| Decreased appetite | 22 | 0 |
| Hypokalemia | 19 | 6 |
Musculoskeletal and connective tissue disorders
|
| Back pain | 19 | 2.5 |
| Muscle spasms | 15 | 0 |
Skin and subcutaneous tissue disorders
|
| Rash | 15 | 2.5 |
| Pruritus | 10 | 1.2 |
Clinically relevant adverse reactions in < 10% of patients with relapsed or refractory DLBCL who received MONJUVI in L-MIND were:
- Blood and lymphatic system disorders: lymphopenia (6%)
- General disorders and administration site conditions: infusion-related reaction (6%)
- Infections: sepsis (4.9%)
- Investigations: weight decreased (4.9%)
- Musculoskeletal and connective tissue disorders: arthralgia (9%), pain in extremity (9%), musculoskeletal pain (2.5%)
- Neoplasms: basal cell carcinoma (1.2%)
- Nervous system disorders: headache (9%), paresthesia (7%), dysgeusia (6%)
- Respiratory, thoracic and mediastinal disorders: nasal congestion (4.9%), exacerbation of chronic obstructive pulmonary disease (1.2%)
- Skin and subcutaneous tissue disorders: erythema (4.9%), alopecia (2.5%), hyperhidrosis (2.5%)
Table 5 summarizes the laboratory abnormalities in L-MIND.
Table 5: Select Laboratory Abnormalities (≥ 20%) Worsening from Baseline in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Who Received MONJUVI in L-MIND| Laboratory Abnormality | MONJUVI in Combination with Lenalidomide |
|---|
All Grades
(%) | Grade 3 or 4
(%) |
|---|
Chemistry
|
| Glucose increased | 49 | 5 |
| Calcium decreased | 47 | 1.4 |
| Gamma glutamyl transferase increased | 34 | 5 |
| Albumin decreased | 26 | 0 |
| Magnesium decreased | 22 | 0 |
| Urate increased | 20 | 7 |
| Phosphate decreased | 20 | 5 |
| Creatinine increased | 20 | 1.4 |
| Aspartate aminotransferase increased | 20 | 0 |
Coagulation
|
| Activated partial thromboplastin time increased | 46 | 4.1 |
Relapsed or Refractory Follicular Lymphoma
The safety of MONJUVI in patients with relapsed or refractory FL was evaluated in the inMIND trial [see Clinical Studies (14.2)]. Patients received MONJUVI 12 mg/kg (N = 274) or placebo (N = 272) intravenously for a maximum of 12 cycles in combination with lenalidomide 20 mg (Days 1-21 of Cycles 1 to 12) and rituximab 375 mg/m2 (Cycles 1 to 5). MONJUVI was administered as follows:
- Cycle 1 to 3: Days 1, 8, 15, and 22 of each 28-day cycle;
- Cycles 4 to 12: Days 1 and 15 of each 28-day cycle.
In the MONJUVI arm, 54% of patients completed all 12 cycles. The median age in that arm was 64 years (range: 36-88 years); 20% were age 75 years or older; 55% were male; 80% were White, 15% Asian, and 0.4% Black.
In the MONJUVI arm, serious adverse reactions occurred in 33% of patients, including serious infections in 24% of patients (including pneumonia and COVID-19 infection). Other serious adverse reactions in ≥ 2% of patients included renal insufficiency (3.3%), second primary malignancies (2.9%), and febrile neutropenia (2.6%). Fatal adverse reactions occurred in 1.5% of patients, including from COVID‑19, sepsis, and adenocarcinoma.
Adverse reactions led to permanent discontinuation of MONJUVI in 11% of patients and dosage interruptions in 74%. The most frequent adverse reactions leading to dosage interruptions of MONJUVI were neutropenia (37% of all patients), COVID-19 (22%), pneumonia (11%), and infusion-related reaction (8%).
The most common adverse reactions (≥ 20%) in recipients of MONJUVI, excluding laboratory abnormalities, were respiratory tract infections (including COVID-19 infection and pneumonia), diarrhea, rash, fatigue, constipation, musculoskeletal pain, and cough. The most common Grade 3 or 4 laboratory abnormalities (≥ 20%) were decreased neutrophils and decreased lymphocytes.
Table 6 summarizes the adverse reactions in inMIND. Adverse reactions occurring at least 5% more frequently in the MONJUVI arm included COVID-19 infection, pneumonia, diarrhea, pruritus, fatigue, musculoskeletal pain, and mucositis.
Table 6: Adverse Reactions (≥ 10%) in Patients with Relapsed or Refractory Follicular Lymphoma Who Received MONJUVI in inMIND| Adverse Reaction
| MONJUVI in Combination with Lenalidomide and Rituximab (N = 274) |
Placebo in Combination with Lenalidomide and Rituximab
(N = 272)
|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
| Infections |
| Respiratory tract infection | 56 | 18 | 56 | 9 |
COVID-19 infection | 34 | 10 | 24 | 2.9 |
Pneumonia | 18 | 14 | 11 | 7 |
Upper respiratory tract infection | 17 | 1.1 | 22 | 0.4 |
| Gastrointestinal disorders |
| Diarrhea | 38 | 0.7 | 28 | 1.8 |
| Constipation | 29 | 0.7 | 25 | 0 |
| Nausea | 18 | 0.4 | 14 | 0.4 |
| Abdominal pain | 13 | 0 | 18 | 2.2 |
| Skin and subcutaneous tissue disorders |
Rash
| 37 | 3.6 | 33 | 1.5 |
| Pruritus | 16 | 0.4 | 10 | 0 |
| General disorders |
| Fatigue | 34 | 2.9 | 25 | 0.7 |
| Pyrexia | 19 | 1.8 | 16 | 2.2 |
| Mucositis | 17 | 0.4 | 11 | 0 |
Edema
| 11 | 0.7 | 17 | 1.1 |
| Musculoskeletal and connective tissue disorders |
| Musculoskeletal pain | 24 | 0.4 | 16 | 0.4 |
| Muscle contracture | 18 | 0 | 19 | 0 |
| Respiratory, thoracic and mediastinal disorders |
| Cough | 21 | 0 | 19 | 0 |
| Procedural complications |
| Infusion-related reaction | 16 | 0.7 | 16 | 0.4 |
Nervous system disorders
|
| Peripheral neuropathy | 12 | 0 | 11 | 0.4 |
| Headache | 10 | 0.4 | 7 | 0 |
| Metabolism and nutrition disorders |
| Decreased appetite | 10 | 0 | 9 | 0.7 |
| The table includes a combination of grouped and ungrouped terms. Adverse reactions were graded using NCI CTCAE version 5.0 |
In the MONJUVI arm, clinically relevant adverse reactions in < 10% of patients with relapsed or refractory FL included thrombosis, febrile neutropenia, second primary malignancy, sepsis, interstitial lung disease, and tumor lysis syndrome.
Table 7 summarizes the laboratory abnormalities in inMIND. Grade 4 laboratory abnormalities in > 1% of patients included neutrophils decreased (19%), platelets decreased (4%) and lymphocytes decreased (1.8%).
Table 7: Select Laboratory Abnormalities (> 20%) Worsening from Baseline in Patients with Relapsed or Refractory Follicular Lymphoma Who Received MONJUVI in inMINDLaboratory Abnormality
| MONJUVI in Combination with Lenalidomide and Rituximab
| Placebo in Combination with Lenalidomide and Rituximab |
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
| Hematology |
| Neutrophils decreased | 75 | 48 | 71 | 44 |
| Hemoglobin decreased | 60 | 9 | 54 | 7 |
| Lymphocytes decreased | 57 | 22 | 51 | 19 |
| Platelets decreased | 40 | 8 | 43 | 9 |
Chemistry
|
| Alanine aminotransferase increased | 47 | 1.5 | 42 | 1.5 |
| Alkaline phosphatase increased | 33 | 0 | 27 | 0 |
| Creatinine increased | 29 | 1.5 | 30 | 0.7 |
| Aspartate aminotransferase increased | 29 | 0 | 31 | 0.4 |
Glucose increased
| 28 | 0.4 | 28 | 1.1 |
| Potassium decreased | 24 | 3.3 | 24 | 3 |
| Sodium decreased | 24 | 1.5 | 22 | 0.4 |